Discover

EDAP
Edap TMS SA
4.32
1 x 3.30
1 x 4.43
bid
ask
+
0.00
0.00%
1 @ 04:00 PM
4.53 +0.21 (4.81%)
Ytd31.31%
1y144.07%
4.32
day range
4.32
2.14
52 week range
8.50
Open4.46Prev Close4.32Low4.32High4.32Mkt Cap82.37M
Vol56.37KAvg Vol161.81KEPS-0.62P/EN/AForward P/E-4.72
Beta0.38Short Ratio0.22Inst. Own42.45%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0750-d Avg2.53200-d Avg4.661yr Est10.67
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-072024-09-0.16-0.19-0.03-18.75%
2024-08-282024-06-0.14-0.18-0.04-28.57%
2024-05-162024-03-0.1-0.13-0.03-30.00%
2024-03-272023-12-0.02-0.15-0.13-650.00%
2023-11-092023-09-0.11-0.12-0.01-9.09%
2023-08-242023-06-0.03-0.14-0.11-366.67%
Upgrade / Downgrade
DateFirmActionFromTo
2024-08-29HC Wainwright & Co.UpgradeBuyBuy
2024-07-22HC Wainwright & Co.UpgradeBuyBuy
2024-05-17HC Wainwright & Co.UpgradeBuyBuy
2024-04-01HC Wainwright & Co.UpgradeBuyBuy
2023-11-10Piper SandlerUpgradeOverweightOverweight
2023-08-25HC Wainwright & Co.UpgradeBuyBuy
Profile
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Soleus Capital Management, L.P.7.31M16.23M19.70%
2024-09-29Morgan Stanley3.37M7.48M9.08%
2024-09-29Rock Springs Capital Management, LP1.57M3.48M4.23%
2024-09-29Archon Capital Management LLC1.06M2.36M2.86%
2024-09-29Bruce & Co, Inc.553.65K1.23M1.49%
2024-09-29Apis Capital Advisors, LLC540.00K1.20M1.46%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Bruce & Co., Inc.529.79K1.18M1.43%
2024-07-30Federated Hermes Kaufmann Fund395.00K876.90K1.06%
2024-07-30Federated Hermes Kaufmann Small Cap Fund395.00K876.90K1.06%
2024-08-30Trust for Professional Managers-ActivePassive International Equity ETF26.65K59.15K0.07%
2024-10-30Fidelity NASDAQ Composite Index Fund22.76K50.54K0.06%
2024-09-29Federated Hermes Kaufmann Fund II4.13K9.16K0.01%